OA
Oak Associates Portfolio holdings
AUM
$1.53B
This Quarter Return
+6.76%
1 Year Return
+20.93%
3 Year Return
+113.44%
5 Year Return
+164.39%
10 Year Return
+515.4%
AUM
$1.01B
AUM Growth
+$1.01B
(+4.4%)
Cap. Flow
-$27.9M
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
36.11%
Holding
179
New
10
Increased
53
Reduced
44
Closed
13
Top Buys
| 1 |
PepsiCo
PEP
|
$11.9M |
| 2 |
Meta Platforms (Facebook)
META
|
$7.84M |
| 3 |
GSK
GSK
|
$4.2M |
| 4 |
Alphabet (Google) Class C
GOOG
|
$3.82M |
| 5 |
Microsoft
MSFT
|
$2.97M |
Top Sells
| 1 |
Gen Digital
GEN
|
$12.6M |
| 2 |
JPMorgan Chase
JPM
|
$10M |
| 3 |
Charles Schwab
SCHW
|
$9.64M |
| 4 |
Cisco
CSCO
|
$9.54M |
| 5 |
IM
Ingram Micro
IM
|
$7.03M |
Sector Composition
| 1 | Technology | 33.7% |
| 2 | Financials | 24.98% |
| 3 | Healthcare | 11.87% |
| 4 | Communication Services | 11.23% |
| 5 | Consumer Discretionary | 5.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Merck
MRK
$210B
| $3.02M | 0.3% | 51,300 -4,500 | -8% | -$265K |
|
77
DaVita
DVA
$9.85B
| $3.02M | 0.3% | 47,000 +1,200 | +3% | +$77K |
|
78
Quest Diagnostics
DGX
$20.3B
| $2.91M | 0.29% | 31,700 -300 | -0.9% | -$27.6K |
|
|
CSRA
79
DELISTED
CSRA Inc.
CSRA
| $2.91M | 0.29% | 91,431 | – | – |
|
80
Marvell Technology
MRVL
$54.2B
| $2.89M | 0.29% | 208,400 -20,339 | -9% | -$282K |
|
81
Gentex
GNTX
$6.15B
| $2.87M | 0.28% | 145,790 +10,260 | +8% | +$202K |
|
82
UnitedHealth
UNH
$281B
| $2.74M | 0.27% | 17,100 | – | – |
|
83
V2X
VVX
$1.81B
| $2.68M | 0.26% | 112,179 -5,023 | -4% | -$120K |
|
84
Assurant
AIZ
$10.9B
| $2.65M | 0.26% | 28,550 +2,250 | +9% | +$209K |
|
85
Sanofi
SNY
$121B
| $2.64M | 0.26% | 65,200 | – | – |
|
86
Cirrus Logic
CRUS
$5.86B
| $2.54M | 0.25% | 44,850 -10,600 | -19% | -$599K |
|
|
STJ
87
DELISTED
St Jude Medical
STJ
| $2.53M | 0.25% | 31,500 | – | – |
|
88
Johnson & Johnson
JNJ
$427B
| $2.5M | 0.25% | 21,700 | – | – |
|
|
AET
89
DELISTED
Aetna Inc
AET
| $2.5M | 0.25% | 20,160 | – | – |
|
90
Stryker
SYK
$150B
| $2.43M | 0.24% | 20,300 -2,650 | -12% | -$317K |
|
91
Biogen
BIIB
$19.4B
| $2.38M | 0.23% | 8,380 +430 | +5% | +$122K |
|
92
CSG Systems International
CSGS
$1.85B
| $2.37M | 0.23% | 48,874 +575 | +1% | +$27.8K |
|
93
Charles River Laboratories
CRL
$8.04B
| $2.32M | 0.23% | 30,400 -1,200 | -4% | -$91.4K |
|
94
Northrop Grumman
NOC
$84.5B
| $2.29M | 0.23% | 9,850 -1,609 | -14% | -$374K |
|
|
ENDP
95
DELISTED
Endo International plc
ENDP
| $2.28M | 0.23% | 138,570 +42,870 | +45% | +$706K |
|
96
Great Southern Bancorp
GSBC
$717M
| $2.27M | 0.22% | 41,552 -16,687 | -29% | -$912K |
|
97
Cigna
CI
$80.3B
| $1.87M | 0.18% | 14,000 | – | – |
|
|
WOOF
98
DELISTED
VCA Inc.
WOOF
| $1.76M | 0.17% | 25,700 -12,900 | -33% | -$885K |
|
99
Eli Lilly
LLY
$657B
| $1.66M | 0.16% | 22,500 | – | – |
|
100
Medtronic
MDT
$119B
| $1.55M | 0.15% | 21,742 -5,676 | -21% | -$404K |
|